1. Medtech Insight
  2. >>Digital Technologies

Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

 
• By Marion Webb

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.

HemoSphere
• Source: Edwards Lifesciences

ICU doctors and surgeons often need to analyze large volumes of complex heterogeneous data to make life-critical decisions for patients. Edwards Lifesciences’ corporate vice president and general manager of critical care, Katie Szyman, believes that the introduction of artificial intelligence (AI) and machine learning will play an increasingly important role in helping doctors predict adverse outcomes before they happen, better manage patients and reduce complications.

Szyman recently sat down with Medtech Insight for a virtual interview to discuss how she and her team are using AI-driven minimally invasive and noninvasive tools in hemodynamic monitoring to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

DeepLook AI Imaging Provides A Deeper Look At Dense Breast

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 
• By Natasha Barrow

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 
• By Barnaby Pickering

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

More from Medtech Insight

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.